Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ROIV Roivant Sciences Ltd.

交易中 09-27 10:38:49 EDT

11.51

-0.06

-0.52%

最高11.66	最低11.42	成交量123.70万
今开11.56	昨收11.57	日振幅2.03%
总市值85.12亿	流通市值41.13亿	总股本7.40亿
成交额1,424万	换手率0.35%	流通股本3.57亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":11.51,"timestamp":1727447919384,"preClose":11.57,"halted":0,"volume":1237030,"delay":0,"floatShares":357340864,"shares":739521824,"eps":5.652036,"marketStatus":"交易中","marketStatusCode":2,"change":-0.06,"latestTime":"09-27 10:38:49 EDT","open":11.56,"high":11.655,"low":11.42,"amount":14241025.83216,"amplitude":0.020311,"askPrice":11.52,"askSize":1003,"bidPrice":11.51,"bidSize":1700,"shortable":3,"etf":0,"ttmEps":5.652036,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1727467200000},"adr":0,"listingDate":1607403600000,"adjPreClose":11.57,"preHourTrading":{"tag":"盘前","latestPrice":11.59,"preClose":11.57,"latestTime":"09:27 EDT","volume":1620,"amount":18789.735239999998,"timestamp":1727443670060},"postHourTrading":{"tag":"盘后","latestPrice":11.6,"preClose":11.57,"latestTime":"19:01 EDT","volume":30330,"amount":350969.7,"timestamp":1727391708188},"volumeRatio":0.379129,"impliedVol":0.28,"impliedVolPercentile":0.2063},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2468583567","title":"BUZZ-Roivant因Organon同意以高达12亿美元的价格收购其部门而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2468583567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468583567?lang=zh_cn&edition=full","pubTime":"2024-09-18 20:20","pubTimestamp":1726662022,"startTime":"0","endTime":"0","summary":"    9月18日 - ** Roivant Sciences   股价盘前上涨2.5%至12.35美元** 医疗保健公司Organon   称， ，该公司已同意以12亿美元收购皮肤疗法开发商Dermavant。** 该交易将使 OGN 获得 Dermavant 的银屑病药膏 VTAMA，该药膏于 2022 年 5 月获得美国 FDA 批准。** 作为交易的一部分，OGN 将支付 1.75 亿美元的预付款以及高达 9.5 亿美元的里程碑付款** OGN 预计在今年第四季度完成交易** 截至上次收盘，ROIV 股价年累计上涨 7.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4559","LU2065171311.SGD","BK4588","LU2065170008.USD","BK4585","BK4007","LU2065171402.SGD","LU2065169927.USD","OGN","BK4139"],"gpt_icon":0},{"id":"2468300195","title":"更新版 1-Organon 拟以高达 12 亿美元的价格收购皮肤疗法开发商 Dermavant","url":"https://stock-news.laohu8.com/highlight/detail?id=2468300195","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468300195?lang=zh_cn&edition=full","pubTime":"2024-09-18 19:55","pubTimestamp":1726660516,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (第 2-4 段增加了交易细节)    路透9月18日 - 医疗保健公司Organon   周三表示，已同意以不超过12亿美元的价格收购Roivant   旗下皮肤疗法开发商Dermavant。Organon公司将支付1.75亿美元的预付款，以及7500万美元的里程碑付款，在达到某些商业里程碑时最高支付9.5亿美元。Dermavant 的 VTAMA 银屑病膏于 2022 年 5 月获得美国食品和药物管理局批准。银屑病是一种常见的慢性炎症性皮肤病。公司预计将在今年第四季度完成交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","OGN","ROIV","BK4588","BK4559","BK4585","LU2065171402.SGD","BK4007","LU2065170008.USD","BK4139","LU2065169927.USD"],"gpt_icon":0},{"id":"2468307175","title":"Organon 将以高达 12 亿美元的价格收购疗法开发商 Dermavant","url":"https://stock-news.laohu8.com/highlight/detail?id=2468307175","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468307175?lang=zh_cn&edition=full","pubTime":"2024-09-18 19:37","pubTimestamp":1726659434,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月18日 - 医疗保健公司Organon   周三表示，已同意以不超过12亿美元的价格收购Roivant   旗下的Dermavant公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","BK4585","LU2065171311.SGD","BK4588","BK4139","LU2065171402.SGD","OGN","ROIV","LU2065169927.USD","BK4007","LU2065170008.USD"],"gpt_icon":0},{"id":"2460736683","title":"Roivant Sciences Ltd.2024财年第二财季实现净利润95.30百万美元，同比增加132.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460736683","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460736683?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:00","pubTimestamp":1723910430,"startTime":"0","endTime":"0","summary":"8月18日，Roivant Sciences Ltd.公布财报，公告显示公司2024财年第二财季净利润为95.30百万美元，同比增加132.64%；其中营业收入为55.13百万美元，同比增加155.00%，每股基本收益为0.13美元。从资产负债表来看，Roivant Sciences Ltd.总负债6.01亿美元，其中短期债务21.49百万美元，资产负债比为10.81，流动比率为27.92。机构评级：截至2024年8月18日，当前有9家机构对Roivant Sciences Ltd.目标价做出预测，其中目标均价为16.67美元，其中最低目标价为12.00美元，最高目标价为22.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180000529f34026f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180000529f34026f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ROIV"],"gpt_icon":0},{"id":"2458341167","title":"Roivant Sciences Ltd.盘中异动 大幅上涨5.01%报10.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458341167","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458341167?lang=zh_cn&edition=full","pubTime":"2024-08-09 00:33","pubTimestamp":1723134784,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日00时33分，Roivant Sciences Ltd.股票出现异动，股价急速拉升5.01%。截至发稿，该股报10.68美元/股，成交量261.747万股，换手率0.35%，振幅6.24%。Roivant Sciences Ltd.股票所在的生物技术行业中，整体涨幅为2.93%。Roivant Sciences Ltd.公司简介：Roivant Sciences Ltd是一家处于商业阶段的生物制药公司，致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809003304941ff810&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809003304941ff810&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2446348888","title":"BUZZ-BuzzFeed 因 Vivek Ramaswamy 报告增持股份而大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2446348888","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446348888?lang=zh_cn&edition=full","pubTime":"2024-06-25 02:24","pubTimestamp":1719253447,"startTime":"0","endTime":"0","summary":"    6月24日 - ** 数字媒体公司 BuzzFeed   周一股价大涨 16.2%，至 2.48 美元，原因是前总统候选人维韦克-拉马斯瓦米继续开展激进活动。** 5 月 22 日，在 Ramaswamy 首次透露持有 BZFD 7.7% 的股份后，BZFD 的股价一度飙升至 4.56 美元，收盘时上涨 20% 至 3.01 美元，Ramaswamy 称他将与公司董事会讨论实现股东价值最大化的战略机遇，包括公司战略的转变。** 随着本交易日的走势，BZFD 的股价在 2023 年和 2022 年分别暴跌~64%和~87%之后，今年累计上涨近 150","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BZFD","BUZZ","BK4587","BK4139","BK4077","BK4111","ROIV","BK4007"],"gpt_icon":0},{"id":"2444369354","title":"坎托菲茨杰拉德公司：重申Roivant Sciences(ROIV.US)增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2444369354","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444369354?lang=zh_cn&edition=full","pubTime":"2024-06-18 22:07","pubTimestamp":1718719624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2440761419","title":"Roivant Sciences Ltd.盘中异动 下午盘急速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440761419","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440761419?lang=zh_cn&edition=full","pubTime":"2024-06-04 02:40","pubTimestamp":1717440053,"startTime":"0","endTime":"0","summary":"北京时间2024年06月04日02时40分，Roivant Sciences Ltd.股票出现波动，股价大幅上涨5.02%。截至发稿，该股报10.88美元/股，成交量297.808万股，换手率0.40%，振幅5.36%。Roivant Sciences Ltd.股票所在的生物技术行业中，整体涨幅为1.39%。Roivant Sciences Ltd.公司简介：Roivant Sciences Ltd 是一家生物制药公司，致力于改善为患者提供的医疗保健服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604024054aef31f5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604024054aef31f5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2439916457","title":"Roivant Sciences Ltd.2024财年实现净利润43.49亿美元，同比增加486.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439916457","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439916457?lang=zh_cn&edition=full","pubTime":"2024-05-31 23:08","pubTimestamp":1717168137,"startTime":"0","endTime":"0","summary":"5月31日，Roivant Sciences Ltd.公布财报，公告显示公司2024财年净利润为43.49亿美元，同比增加486.92%；其中营业收入为1.25亿美元，同比增加103.98%，每股基本收益为5.55美元。从资产负债表来看，Roivant Sciences Ltd.总负债7.74亿美元，其中短期债务21.89百万美元，资产负债比为9.34，流动比率为25.22。机构评级：截至2024年5月31日，当前有10家机构对Roivant Sciences Ltd.目标价做出预测，其中目标均价为16.58美元，其中最低目标价为12.00美元，最高目标价为20.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024053123090595803053&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024053123090595803053&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ROIV"],"gpt_icon":0},{"id":"2439961659","title":"HC Wainwright &amp; Co.：重申Roivant Sciences(ROIV.US)评级，由买入调整至买入评级, 目标价由18.","url":"https://stock-news.laohu8.com/highlight/detail?id=2439961659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439961659?lang=zh_cn&edition=full","pubTime":"2024-05-31 18:38","pubTimestamp":1717151905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2424229188","title":"Roivant Sciences Ltd.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424229188","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2424229188?lang=zh_cn&edition=full","pubTime":"2024-04-04 00:51","pubTimestamp":1712163119,"startTime":"0","endTime":"0","summary":"北京时间2024年04月04日00时51分，Roivant Sciences Ltd.股票出现异动，股价大幅拉升5.04%。截至发稿，该股报11.47美元/股，成交量958.497万股，换手率1.19%，振幅7.46%。Roivant Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.24%。Roivant Sciences Ltd.公司简介：Roivant Sciences Ltd 是一家生物制药公司，致力于改善为患者提供的医疗保健服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240404005200861e35b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240404005200861e35b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2424813742","title":"HC Wainwright &amp; Co.：维持Roivant Sciences(ROIV.US)评级，由买入调整至买入评级, 目标价由17.","url":"https://stock-news.laohu8.com/highlight/detail?id=2424813742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2424813742?lang=zh_cn&edition=full","pubTime":"2024-04-03 19:05","pubTimestamp":1712142316,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2424019130","title":"BUZZ-抗炎药物在中期研究中获得成功后，Roivant 公司业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2424019130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2424019130?lang=zh_cn&edition=full","pubTime":"2024-04-02 20:08","pubTimestamp":1712059733,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月2日 - ** Roivant Sciences   股价在盘前交易中上涨7.4%，报11.20美元 ** 该公司称其治疗非传染性葡萄膜炎的试验性药物在一项中期研究中有助于减轻炎症性眼病的症状 (link) ** 在对26名患者进行的测试研究中，接受较高强度45毫克(mg) 剂量治疗的患者中有29%出现治疗失败，而接受15毫克剂量治疗的患者中有44%出现治疗失败，较低的治疗失败率意味着该药物的益处更大。** 布雷博西替尼这种药物还有助于减轻一些接受高剂量治疗的患者的黄斑水肿。** 截至上一交易日收盘，股价年累计下跌约 7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BUZZ","BK4139"],"gpt_icon":0},{"id":"2424979260","title":"Roivant公司的抗炎药物在中期研究中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2424979260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2424979260?lang=zh_cn&edition=full","pubTime":"2024-04-02 19:00","pubTimestamp":1712055650,"startTime":"0","endTime":"0","summary":" Bhanvi Satija    路透社4月2日 - Roivant Sciences   周二称，在一项中期研究中，其治疗非感染性葡萄膜炎的实验性药物有助于减轻炎症性眼病的症状。目前唯一获批的针对非感染性葡萄膜炎病因的疗法是艾伯维的   Humira，该药已于2023年停止专利。Roivant公司周二还表示，公司董事会已经批准了一项回购价值高达15亿美元公司股票的计划，其中包括从住友制药  回购6.48亿美元的股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0289739699.SGD","SG9999001176.USD","BK4588","LU1023059063.AUD","BK4007","IE00B19Z3B42.SGD","BK4581","PFE","SG9999011175.SGD","SG9999001176.SGD","LU0170899867.USD","BK4585","LU1057294990.SGD","LU0234572021.USD","SG9999003800.SGD","LU0868494617.USD","SG9999013999.USD","BK4139","IE00BLSP4452.SGD","ROIV","IE00BLSP4239.USD","BK4592","BK4534","IE0002270589.USD","SG9999002224.SGD","SG9999002232.USD","BK4568","BK4550","LU0456855351.SGD","SGXZ57979304.SGD","LU1066051498.USD","IE00BBT3K403.USD","BK4533","LU0122379950.USD","LU1066053197.SGD","LU0058720904.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":-0.0236},{"period":"3month","weight":0.0946},{"period":"6month","weight":0.0977},{"period":"1year","weight":-0.1228},{"period":"ytd","weight":0.0303}],"compareEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0516},{"period":"6month","weight":0.0941},{"period":"1year","weight":0.3433},{"period":"ytd","weight":0.2041}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Roivant Sciences Ltd.是一家于2020年7月6日成立的注册于百慕大群岛的公司。Roivant的使命是通过将每一个低效率都视为机会来改善为患者提供的医疗保健服务。Roivant通过以创造性的方式构建技术和培养人才，利用Roivant平台推出“Vants”——灵活且专注的生物制药和健康技术公司，从而更快地开发变革性药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.091624},{"month":2,"riseRate":0.25,"avgChangeRate":0.003027},{"month":3,"riseRate":0,"avgChangeRate":-0.105559},{"month":4,"riseRate":0.75,"avgChangeRate":-0.013041},{"month":5,"riseRate":0.5,"avgChangeRate":0.053964},{"month":6,"riseRate":0.75,"avgChangeRate":0.012477},{"month":7,"riseRate":0.75,"avgChangeRate":0.048723},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002132},{"month":9,"riseRate":0.25,"avgChangeRate":-0.050066},{"month":10,"riseRate":0.333333,"avgChangeRate":0.061732},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.005235},{"month":12,"riseRate":1,"avgChangeRate":0.39524}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况